| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种调控叶绿体发育及光合速率的蛋白质及其基因和应用 | CN201310396837.8 | 2013-09-04 | CN103497939A | 2014-01-08 | 魏祥进; 胡培松; 唐绍清; 邵高能; 焦桂爱; 谢黎虹; 圣忠华; 宋建; 刘聪利 |
| 本发明公开了一种调控叶绿体发育及光合速率的蛋白质及其基因和应用。该基因编码蛋白是具有SEQIDNO:2所示的氨基酸序列，该编码基因具有SEQIDNO:1所示的核苷酸序列。该水稻叶绿体发育编码基因发生突变可导致幼叶、剑也以及幼穗白化，近光合速率减弱。将其应用于植物遗传改良等工作，是重要的指示基因，可作为目的基因应用于杂交水稻制种，可以方便检测杂交后代的纯度，将其过量表达有利于提高植物的光合作用，可应用于植物高光效育种。 | ||||||
| 2 | Solubility and Affinity Tag for Recombinant Protein Expression and Purification | US15015727 | 2016-02-04 | US20170226489A1 | 2017-08-10 | Peng Liang |
| Systems and methods of coding for and isolating a fusion protein are provided. The fusion protein may be expressed by a DNA sequence and comprise an adenylate kinase linked by its carboxy-terminus to a biologically active polypeptide or protein. Later processing steps include isolating the biologically active polypeptide or protein via affinity elution of the fusion proteins with substrate analog of adenylate kinase. | ||||||
| 3 | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent | US185438 | 1994-01-21 | US5676978A | 1997-10-14 | Beverly A. Teicher; Donald W. Kufe; Rima Kaddurah-Daouk |
| The present invention provides for the use of creatine compounds and hyperplastic inhibitory agents for prophylactic and/or therapeutic treatments of undesirable cell growth, e.g. tumors. The present invention provides methods of using creatine compounds, in combination with a hyperplastic inhibitory agent, to inhibit the growth of undesirable cells in a subject. The present invention is based, at least in part, on the discovery that creatine compounds and hyperplastic inhibitory agents, such as inhibitory agents, additively and synergistically combine to inhibit cell growth. The present invention further pertains to compositions for inhibiting undesirable cell growth in a subject. The compositions of the present invention include an effective amount of the creatine compound and a hyperplastic inhibitory agent in a pharmaceutically acceptable carrier. Other aspects of the invention include packaged creatine compounds and inhibitory agents. The packaged compounds and agents also include instructions for using the creatine compound/inhibitory agent combination for inhibiting undesirable cell growth in a patient or instructions for using the compounds and agents, in selected quantities, in a pharmaceutically acceptable carrier. | ||||||
| 4 | 熱安定性アッセイ試薬 | JP2014530316 | 2012-09-14 | JP6082999B2 | 2017-02-22 | サットン ジョン マーク; スキッパー フィリップ ジェームズ アリスター |
| 5 | JPH07502533A - | JP51185692 | 1992-12-21 | JPH07502533A | 1995-03-16 | |
| 6 | ANTIBACTERIAL COMPOSITION FOR COMBATING CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA COMPRISING ADK PROTEIN AS ACTIVE INGREDIENT | US15563795 | 2016-04-04 | US20180078619A1 | 2018-03-22 | Yeong Min PARK; In Duk JUNG; Seung Jun LEE |
| Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition. | ||||||
| 7 | Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof | US15024636 | 2014-09-25 | US09878004B2 | 2018-01-30 | Alison Williams; Michael J. Hamill; Nathaniel W. Silver; Ying-Ja Chen; David Arthur Berry; David V. Erbe; Chung-Wei Lee; Luke Hamm |
| Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations. | ||||||
| 8 | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | US610418 | 1990-11-07 | US5324731A | 1994-06-28 | Rima Kaddurah-Daouk; James W. Lillie; Jonathan J. Burbaum |
| A method of inhibiting growth, transformation and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted. | ||||||
| 9 | 熱安定性アッセイ試薬 | JP2014530316 | 2012-09-14 | JP2014531206A | 2014-11-27 | ジョン マーク サットン; フィリップ ジェームズ アリスター スキッパー |
| (i)熱安定性キナーゼと、(ii)単一ドメイン抗体又は単一ドメイン抗体断片とを含む単鎖融合タンパク質が提供される。単一ドメイン抗体又は単一ドメイン抗体断片を調製する方法であって、(i)大腸菌などの宿主細胞において単一ドメイン抗体又は抗体断片を熱安定性キナーゼとの単鎖融合タンパク質として発現させるステップと、(ii)融合タンパク質を宿主細胞の細胞質から精製するステップとを含む方法も提供される。 | ||||||
| 10 | JPH06506666A - | JP50016691 | 1991-11-07 | JPH06506666A | 1994-07-28 | |
| 11 | JPH04506058A - | JP50435690 | 1990-02-14 | JPH04506058A | 1992-10-22 | |
| 12 | Method for the Identification of Inhibitors and Activators of Thymidylate Kinases | US15493509 | 2017-04-21 | US20170306388A1 | 2017-10-26 | Gordon Steven Rule; Kaustubh Sinha |
| Provided herein is a method of producing large amounts of the enzyme thymidylate kinase from multiple species for drug discovery purposes. Also provided herein are NMR methods of monitoring a reaction involving a thymidine kinase. | ||||||
| 13 | METHOD FOR EVALUATING MESENCHYMAL STEM CELL ACTIVITY, METHOD FOR CULTURING MESENCHYMAL STEM CELLS, METHOD FOR PRODUCING THERAPEUTIC AGENT FOR LIVER DYSFUNCTION, AND THERAPEUTIC AGENT FOR LIVER DYSFUNCTION | US15512390 | 2015-08-19 | US20170246211A1 | 2017-08-31 | Isao SAKAIDA; Shuji TERAI; Taro TAKAMI; Koichi FUJISAWA; Naoki YAMAMOTO; Kenji YONEDA |
| The present invention relates to a method for evaluating the activity level of mesenchymal stem cells, and a method for culturing mesenchymal stem cells using the evaluation method in the field of culturing mesenchymal stem cells for regenerative medicine, and further, a method for producing a therapeutic agent for liver dysfunction and a therapeutic agent for liver dysfunction. This method for evaluating mesenchymal stem cell activity according to the present invention comprises an assay step for assaying the amount of adenylate kinase 4 (AK4) in the mesenchymal stem cells; and a determination step for determining the activity level of the mesenchymal stem cells from the assayed amount of adenylate kinase 4.In this method, the activity level of mesenchymal stem cells can be evaluated from the assayed amount of AK4, for instance, if the mitochondrial activity level of mesenchymal stem cells is high, the mesenchymal stem cells can be evaluated as ideal for use as a therapeutic agent, while if mitochondrial activity of the mesenchymal stem cells is low and aging does not proceed, the mesenchymal stem cells can be evaluated as suitable for subculture. | ||||||
| 14 | THERMOSTABLE ASSAY REAGENTS | US14344771 | 2012-09-14 | US20140315215A1 | 2014-10-23 | John Mark Sutton; Philip James Alister Skipper |
| There is provided a single-chain fusion protein comprising: (i) a thermostable kinase and (ii) a single-domain antibody or single-domain antibody fragment. There is also provided a method of preparing a single-domain antibody or single-domain antibody fragment, the method comprising: (i) expressing the single-domain antibody or antibody fragment as a single-chain fusion protein with a thermostable kinase, in a host cell such as E. coli; and (ii) purifying the fusion protein from the cytoplasm of the host cell. | ||||||
| 15 | METHOD FOR AMPLIFYING ADENOSINE TRIPHOSPHATE AND METHOD AND REAGENT FOR DETECTING THE CONCENTRATION OF MICROORGANISMS | US12954824 | 2010-11-26 | US20120034635A1 | 2012-02-09 | Ching-Yi Hsu; Meng-Shun Huang; Hwan-You Chang; Hui-Ju Lee; Ming-Rong Ho |
| A method for amplifying adenosine triphosphate is provided, including mixing adenosine triphosphate sulfurylase, adenosine 5′ phosphosulfate, adenylate kinase, uridine triphosphate, acetate kinase, acetyl phosphate, luciferin and luciferase in the presence of ATP to form a mixture, and reacting the mixture to amplify ATP. A method and reagent for detecting a concentration of microorganisms are also provided. | ||||||
| 16 | 27803, a novel human adenylate kinase family member and uses therefor | US09925108 | 2001-08-08 | US20020061575A1 | 2002-05-23 | Rachel Meyers |
| The invention provides isolated nucleic acids molecules, designated 27803 nucleic acid molecules, which encode novel adenylate kinase family member family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27803 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27803 gene has been introduced or disrupted. The invention still further provides isolated 27803 proteins, fusion proteins, antigenic peptides and anti-27803 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | ||||||
| 17 | Combined use of .beta.-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides | US57526 | 1993-05-04 | US5374541A | 1994-12-20 | Chi-Huey Wong; Federico C. A. Gaeta |
| A single reaction vessel process for the synthesis of a sialylated galactoside is disclosed. The synthesis utilizes a .beta.-galactosidase to catalyze the reaction of a galactose-containing substrate and an acceptor to form a new galactosyl glycoside that is then sialylated using a cyclic multienzyme synthesis system to form CMP-sialic acid that sialylates the formed galactosyl glycoside in the presence of an .alpha.-sialyltransferase. The value of K.sub.m /V.sub.max for the formed galactosyl glycoside as a substrate for the .alpha.-sialyltransferase is less than one-third the K.sub.m /V.sub.max value for the galactose-containing substrate for that .alpha.-sialyltransferase. | ||||||
| 18 | Creatine analogs having antiviral activity | US812561 | 1991-12-20 | US5321030A | 1994-06-14 | Rima Kaddurah-Daouk; James W. Lillie; Theodore S. Widlanski; Jonathan J. Burbaum; Craig J. Forsyth |
| The present invention relates to the use of analogs of creatine, such as cyclocreatine, as antiviral agents. Analogs of creatine can be used as antiviral agents against a variety of viruses, particularly DNA viruses, such as Herpes viruses (e.g., HSV-1, HSV-2, cytomegaloviruses, Varicella-Zoster virus) and adenovirus. The invention further relates to creatine analogs including four classes of creatine analogs selected as candidate antiviral compounds: (1) creatine analogs that can be phosphorylated by creatine kinase but differ in their phosphoryl group transfer potential, (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine, (3) creatine analogs which can act as irreversible inhibitors of creatine kinase, and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group. | ||||||
| 19 | 근육량, 강도 및 성능을 유지하기 위한 조성물 및 제형, 그리고 이의 생산방법 및 용도 | KR1020167010707 | 2014-09-25 | KR1020160058940A | 2016-05-25 | 실버,나데니얼,더블유.; 첸,잉-자; 베리,데이빗,에이.; 해밀,마이클,제이.; 바수,서바유; 햄,루크; 윌리엄스,앨리슨; 어브,데이빗; 본말챈,제프리 |
| 영양폴리펩타이드가본 명세서에서제공된다. 또한폴리펩타이드를암호화하는핵산, 폴리펩타이드를생성하는재조합미생물, 폴리펩타이드를발현시키기위한벡터, 재조합미생물을이용하는폴리펩타이드의제조방법, 폴리펩타이드를포함하는조성물및 제형및 폴리펩타이드, 조성물및 제형을이용하는방법을포함하는, 다양한다른실시형태가제공된다. | ||||||
| 20 | THERMOSTABLE ASSAY REAGENTS | EP12761794.2 | 2012-09-14 | EP2756081B1 | 2015-07-01 | SUTTON, John Mark; SKIPPER, Philip James Alister |
QQ群二维码
意见反馈
意见反馈